KCTD15 Activators
KCTD15 Activators are a class of chemical compounds that enhance the functional activity of KCTD15, a protein that is involved in ubiquitination and protein-protein interactions. Some KCTD15 activators, such as Forskolin, Rolipram, db cAMP, IBMX, and 8-Bromo-cAMP, increase the levels of cAMP, a secondary messenger in cells. Elevated cAMP levels activate Protein Kinase A (PKA), which can phosphorylate KCTD15, enhancing its functional activity. This process exemplifies how specific signaling pathways can be targeted to increase the functional activity of KCTD15.
Other KCTD15 activators act by triggering compensatory mechanisms that lead to the activation of KCTD15. Compounds like H-89 dihydrochloride and Staurosporine are inhibitors of various kinases. Their inhibitory actions stimulate compensatory mechanisms involving other kinases that can phosphorylate and activate KCTD15. For example, Staurosporine, a protein kinase inhibitor, can result in compensatory mechanisms that can engage other kinases, leading to possible phosphorylation and activation of KCTD15. EGF, on the other hand, is a growth factor that can activate the MAPK pathway, leading to the phosphorylation and activation of KCTD15. This exemplifies how the manipulation of specific signaling pathways can indirectly lead to the activation of KCTD15.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin is an activator of adenyl cyclase, leading to increased cAMP levels. The increase in cAMP activates protein kinase A (PKA), which may phosphorylate KCTD15, enhancing its function. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram is a phosphodiesterase 4 (PDE4) inhibitor. By inhibiting PDE4, Rolipram prevents the breakdown of cAMP, leading to an increase in cAMP levels. This increase can activate PKA, which can phosphorylate and activate KCTD15. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
db cAMP is a cAMP analog that can activate PKA. PKA activation leads to the phosphorylation and activation of KCTD15. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-specific phosphodiesterase inhibitor. By preventing cAMP breakdown, IBMX raises cAMP levels, activating PKA. This activation can result in phosphorylation and activation of KCTD15. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that can activate PKA. This activation can lead to phosphorylation and activation of KCTD15. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a non-selective protein kinase inhibitor. Despite its inhibitory action, it can trigger compensatory mechanisms that can engage other kinases, leading to phosphorylation and activation of KCTD15. | ||||||